Supernus Pharmaceuticals, Inc. (SUPN)
45.11
-0.74
(-1.61%)
USD |
NASDAQ |
Aug 24, 16:00
45.11
0.00 (0.00%)
After-Hours: 20:00
Supernus Pharmaceuticals Net Income (Quarterly) : -58.37M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -58.37M |
| March 31, 2026 | -2.293M |
| December 31, 2025 | -4.105M |
| September 30, 2025 | -45.12M |
| June 30, 2025 | 22.50M |
| March 31, 2025 | -11.83M |
| December 31, 2024 | 15.33M |
| September 30, 2024 | 38.50M |
| June 30, 2024 | 19.92M |
| March 31, 2024 | 0.124M |
| December 31, 2023 | 1.175M |
| September 30, 2023 | -15.98M |
| June 30, 2023 | -0.831M |
| March 31, 2023 | 16.95M |
| December 31, 2022 | 25.48M |
| September 30, 2022 | 1.749M |
| June 30, 2022 | 7.865M |
| March 31, 2022 | 25.62M |
| December 31, 2021 | 2.442M |
| September 30, 2021 | 21.56M |
| June 30, 2021 | 23.73M |
| March 31, 2021 | 5.694M |
| December 31, 2020 | 30.77M |
| September 30, 2020 | 40.00M |
| June 30, 2020 | 34.67M |
| Date | Value |
|---|---|
| March 31, 2020 | 21.52M |
| December 31, 2019 | 33.13M |
| September 30, 2019 | 28.86M |
| June 30, 2019 | 32.73M |
| March 31, 2019 | 18.34M |
| December 31, 2018 | 25.89M |
| September 30, 2018 | 28.01M |
| June 30, 2018 | 30.74M |
| March 31, 2018 | 26.35M |
| December 31, 2017 | 13.66M |
| September 30, 2017 | 15.96M |
| June 30, 2017 | 17.37M |
| March 31, 2017 | 10.30M |
| December 31, 2016 | 14.32M |
| September 30, 2016 | 61.83M |
| June 30, 2016 | 10.25M |
| March 31, 2016 | 4.825M |
| December 31, 2015 | 6.852M |
| September 30, 2015 | 4.222M |
| June 30, 2015 | 2.437M |
| March 31, 2015 | 0.738M |
| December 31, 2014 | 4.354M |
| September 30, 2014 | 27.86M |
| June 30, 2014 | 3.202M |
| March 31, 2014 | -15.54M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Indivior Pharmaceuticals, Inc. | 122.00M |
| Pfizer Inc. | -246.00M |
| Amphastar Pharmaceuticals, Inc. | 30.35M |
| Collegium Pharmaceutical, Inc. | -15.05M |
| Bristol Myers Squibb Co. | 3.316B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 219.06M |
| Total Expenses (Quarterly) | 277.43M |
| EPS Diluted (Quarterly) | -1.005 |
| Enterprise Value | 2.335B |
| Gross Profit Margin (Quarterly) | 72.88% |
| Profit Margin (Quarterly) | -26.65% |
| Earnings Yield | -4.24% |
| Normalized Earnings Yield | -2.469 |